News

Mon810 maize is the only transgenic GM plant authorized for commercial cultivation in the European Union. This authorization was initially granted, via France, almost 30 years ago, in 1998, for an initial period of 10 years. A renewal application was submitted in 2007. Since then, no decision has been taken by the European authorities. How this maize, which authorization theoretically expired in 2008, can still be grown legally in Europe? Simply because European law accepts that, as long as the European Commission has not responded to a request for renewal, the initial authorization remains valid. To date, it’s been 15 years that the Commission fails to respond to Bayer/Monsanto’s request.

On 15 October 2024, the European Patent Office (EPO) upheld KWS’s patent for cold-resistant maize. This decision is likely to raise serious concerns among European seed breeders, who may now feel threatened in their breeding work. The patent covers maize plants containing a naturally occurring genetic sequence, which restricts the freedom of breeders to develop new varieties. The “oral proceedings”, which took place before the EPO Opposition Division and which Inf’OGM attended by video-conference, gave rise to some unusual and revealing exchanges. This case shows once again that patents can indeed be tools for appropriating seeds developed by farmers and/or breeders.

In less than a year and a half, from May 3, 2022 to October 12, 2023, the previous European Commission has launched a number of legislative initiatives concerning the Living. The deregulation of GMOs, the digitization of living organisms and even patents are just some of the issues on the table of member states and the European Parliament. If adopted, these projects will make it easier for companies with substantial financial, human and technical resources to take ownership of the Living. These initiatives do echo current international negotiations.

Understanding the absence of any obligation to disclose the origin of the material on which a patented “invention” is based is one of the keys to understanding the ongoing strategy of appropriation of living organisms by a few multinationals. In the field of patents, Inf’OGM has chosen to publish an article shedding light on a […]

After genetic sequences and DNA, here comes RNA, the new flagship molecule in biotechnology that is supposed to solve agricultural and health problems. Companies in this field are flourishing. Among them is GreenLight Biosciences, a company that was on the verge of bankruptcy when it was bought by the investment fund Fall Line Capital.

43 detections of insects having acquired resistance to the Bt proteins supposed to kill them were listed in a scientific article in 2023. 43 cases out of 73 studied, i.e. more than half. For the authors of the article, the use of insecticidal GMOs has been crowned with success, as in several cases it has made it possible to reduce or even eradicate local pests. But failures also occurred due to resistance. The authors believe that the future lies in a combination of technologies, among which is RNA interference.

For almost 15 years, European and French experts have been recommending that Bayer improve environmental monitoring of commercial Mon810 corn crops in Spain and Portugal. This improvement is necessary, they say, to prevent target insects such as the European corn borer and sesamia from developing resistance to the insecticide produced by this transgenic corn. But year after year, Bayer only partially responds to these requests. Yet concerns are becoming increasingly serious and concrete, as demonstrated by the latest EFSA opinion, published in August 2024.

In Norway, the Institute of Marine Research (IMR)i has filed a trial application, in 2023, for genetically modified salmon (VIRGIN® salmon). These salmon, bred in cages in the open sea, would be sterile to prevent them from interbreeding with wild populations in the event of accidental dissemination. The Norwegian Environment Agency asked the Norwegian Scientific Committee for Food and the Environment (VKM) to assess the associated environmental risks. VKM’s opinion was highly critical, stating that there was insufficient evidence to consider the trial safeii. In April 2024, after having considered new data, VKM reiterated its negative opinion on this GM salmon trial.

What are the links between new techniques of genetic modification, digitization of genetic sequences information and patents? Inf’OGM publishes here an analysis presented in June 2024 at a regional workshop organized by the African Center for Biodiversity, in Durban (South Africa). It was written by Guy Kastler, representative of the international farmers’ organization La Via Campesina at various ITPGRFA and CBD meetings.